<DOC>
	<DOCNO>NCT02670083</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel group study evaluate efficacy safety crenezumab versus placebo participant prodromal mild AD . Participants randomize 1:1 receive either intravenous ( IV ) infusion crenezumab placebo every 4 week ( q4w ) 100 week . The final efficacy safety assessment perform 52 week last crenezumab dose .</brief_summary>
	<brief_title>CREAD Study : A Study Crenezumab Versus Placebo Evaluate Efficacy Safety Participants With Prodromal Mild Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Weight 40 120 kilogram ( Kg ) inclusive Availability person ( refer `` caregiver '' ) investigator 's judgment : Has frequent sufficient contact participant able provide accurate information regard participant 's cognitive functional ability , agree provide information clinic visit ( require partner input scale completion ) , sign necessary consent form , sufficient cognitive capacity accurately report upon participant 's behavior cognitive functional ability Fluency language test use study site Adequate visual auditory acuity , investigator 's judgment , sufficient perform neuropsychological testing ( eye glass hear aid permit ) Evidence AD pathological process , positive amyloid assessment either cerebrospinal fluid ( CSF ) amyloid beta 142 level measure Elecsys betaamyloid ( 142 ) test system amyloid PET scan qualitative read core/central PET laboratory Demonstrated abnormal memory function screen Screening mini mental state examination ( MMSE ) score great equal ( &gt; = ) 22 point Clinical Dementia RatingGlobal Score ( CDRGS ) 0.5 1.0 Meets National Institute Aging/Alzheimer 's Association ( NIAAA ) core clinical criterion probable AD dementia prodromal AD ( consistent NIAAA diagnostic criterion guideline mild cognitive impairment ( MCI ) If receive symptomatic AD medication , dose regimen must stable 3 month prior screen Any evidence condition AD may affect cognition dementia , stroke , brain damage , autoimmune disorder ( e.g . multiple sclerosis ) infection neurological sequela . History major psychiatric illness schizophrenia major depression ( consider remission ) At risk suicide opinion investigator Presence significant cerebral vascular pathology assess MRI central reader Unstable clinically significant cardiovascular , kidney liver disease ( e.g. , myocardial infarction ) Uncontrolled hypertension Screening hemoglobin A1c ( HbA1C ) &gt; 8 % Poor peripheral venous access History cancer except : If consider cure If actively treat anticancer therapy radiotherapy Known history severe allergic , anaphylactic , hypersensitivity reaction chimeric , human , humanized antibody fusion protein</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>